Joshua Brody, MD Email Joshua Brody
-
- Position
- ASSISTANT PROFESSOR | Medicine, Hematology and Medical Oncology
-
- Specialties
- Hematology-Oncology
- Cancer (Oncology)
-
- Language
- English
-
- Hospital Affiliation
- The Mount Sinai Hospital
-
- Phone
- Ruttenberg Treatment Center 212-241-6756212-241-6756
Leukemia Lymphoma Society Interview
Immunotransplant for Mantle Cell Lymphoma - ASCO 2011
The Lymphoma Immunotherapy Program at the Mount Sinai School of Medicine and the Brody Lab focus on basic and applied tumor immunology (particularly in lymphoma, melanoma, and ovarian adenocarcinoma). Other areas of interest include: bioinformatic-based collaborations tracking T-cell responses using high-throughput sequencing of the entire TCRbV repertoire and studies of small-molecule inhibitors of lymphocyte signal transduction, e.g. PI3K, mTOR, btk. Our lab has the rare opportunity to both perform correlative studies on primary patient tumor samples from early phase clinical trials and to continually develop advancements in those trials based on what is learned. The core mission is the translation of basic science in tumor immunology into novel clinical trials and development of correlative science associated with those trials to gain a greater understanding of mechanistic-clinical correlates.
PUBLICATIONS:
In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Kim YH, Gratzinger D, Harrison C, Brody JD, Czerwinski DK, Ai WZ, Morales A, Abdulla F, Xing L, Navi D, Tibshirani RJ, Advani RH, Lingala B, Shah S, Hoppe RT, Levy R. Blood. 2012 Jan 12;119(2):355-63. PMID: 22045986
Active and passive immunotherapy for lymphoma: proving principles and improving results. Brody J, Kohrt H, Marabelle A, Levy R. J Clin Oncol. 2011 May 10;29(14):1864-75. PMID: 21482977
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, Müller A, Pachynski R, Czerwinski D, Coutre S, Chao MP, Chen L, Tedder TF, Levy R. Blood. 2011 Feb 24;117(8):2423-32. Epub 2010 Dec 30. PMID:21193697
Idiotype vaccine strategies for treatment of follicular lymphoma. Mahaseth H, Brody JD, Sinha R, Shenoy PJ, Flowers CR. Future Oncol. 2011 Jan;7(1):111-22. Review. PMID:21174542
A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors. Goldstein MJ, Varghese B, Brody JD, Rajapaksa R, Kohrt H, Czerwinski DK, Levy S, Levy R. Blood. 2011 Jan 6;117(1):118-27. PMID: 20876455
In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, Kim YH, Hoppe RT, Knox SJ, Shin LK, Wapnir I, Tibshirani RJ, Levy R. J Clin Oncol. 2010 Oct 1;28(28):4324-32. PMID:20697067
Lymphoma immunotherapy: vaccines, adoptive cell transfer and immunotransplant. Brody J, Levy R. Immunotherapy. 2009 Sep;1(5):809-24. Review. PMID:20636025
Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors. Brody JD, Goldstein MJ, Czerwinski DK, Levy R. Blood. 2009 Jan 1;113(1):85-94. PMID:18812472
A case of complete heart block reverting to normal sinus rhythm after treatment for cardiac invasive Burkitt's lymphoma. Knowles JW, Elliott AB, Brody J. Ann Hematol. 2007 Sep;86(9):687-90. PMID:17410366
Serial cytogenetic alterations resulting in transformation of a low-grade follicular lymphoma to Burkitt lymphoma. Li L, Gupta S, Bashir T, Koduru PR, Brody J, Allen SL. Cancer Genet Cytogenet. 2006 Oct 15;170(2):140-6. PMID: 17011985
Splenic diffuse large B-cell lymphoma ina patient with type 1 Gaucher disease: Diagnostic and therapeutic challenges. Brody JD, Advani R, Shin LK, Bingham DB, Rosenberg SA. Ann Hematol. 2006 Nov;85(11):817-20. PMID:16937096
Treatment of mantle cell lymphoma: current approach and future directions. Brody J, Advani R. Crit Rev Oncol Hematol. 2006 Jun;58(3):257-65. Review. PMID:16751087
Using signaling pathways to overcome immune tolerance to tumors. Engleman EG, Brody J, Soares L. Sci STKE. 2004 Jul 6;2004(241):pe28. Review. PMID: 15252217
DC-based cancer vaccines: lessons from clinical trials. Brody JD, Engleman EG. Cytotherapy. 2004;6(2):122-7. Review. PMID: 15203988
CD28 receptor endocytosis is targeted by mutations that disrupt phosphatidylinositol 3-kinase binding and costimulation. Céfaï D, Schneider H, Matangkasombut O, Kang H, Brody J, Rudd CE. J Immunol. 1998 Mar 1;160(5):2223-30. PMID: 9498761
Certification
Medical Oncology
Clinical Focus
- Adult Non-Hodgkin's Lymphoma
- Hodgkin's Disease
- Hodgkin's Lymphoma
- Leukemia
- Lymphoma
- Mantle Cell Lymphoma
- Primary Central Nervous System Lymphoma
- T Cell Chronic Lymphoid Leukemia
Multi-Disciplinary Training Areas
Cancer Biology [CAB], Immunology [IMM]
Education
BA, Harvard University
MD, SUNY StonyBrook Medical Center
MD, State University of New York Stony Brook School of Medicine
Residency, Internal Medicine
Yale University Health Services
Fellowship, Medical Oncology
Stanford University School of Medicine
Language
English
2011
Society for Immunotherapy of Cancer Presidential Award (SITC 26th Annual Meeting)
Society for the Immunotherapy of Cancer
2011
SCL Award for top abstract submitted to 2011 International Conference on Malignant Lymphoma
Swiss Cancer League
2011
ASCO Merit Award for top 100 abstracts submitted to 2011 Annual Meeting
American Society of Clinical Oncology
2009
Howard Temin Pathway to Independence Award in Cancer Research (K99/R00) – [1 K99 CA140728-01] ”Immunotransplant to Treat Lymphoma” – 09/09 – 08/14
NCI
2009
‘Outstanding Recent Graduate’
SUNY Stony Brook School of Medicine
2008
ASCO Bradley Stuart Beller Foundation Fellowship Merit Award for best abstract submitted to 2008 Annual Meeting
American Society of Clinical Oncology
2008
William Guy Forbeck Scholar Award – invited to present at 2008 Forum
William Guy Forbeck Research Foundation
2008
MCLC featured researcher
Mantle Cell Lymphoma Consortium
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Brody during 2017 and/or 2018. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- Gilead Sciences, Inc.
- Janssen Pharmaceuticals, Inc.
- Seattle Genetics
Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose
- Gilead Sciences, Inc.
- Janssen Pharmaceuticals, Inc.
- Seattle Genetics
Scientific Advisory Board:
- Celgene Corporation
- Gilead Sciences, Inc.
- Janssen Pharmaceuticals, Inc.
- Seattle Genetics
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.